These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30415236)

  • 1. Antithrombotic medications and their impact on fibrin clot structure and function.
    Undas A; Zabczyk M
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma fibrin clot structure and thromboembolism: clinical implications.
    Ząbczyk M; Undas A
    Pol Arch Intern Med; 2017 Dec; 127(12):873-881. PubMed ID: 29225327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized antithrombotic therapy.
    Lüscher TF; Steffel J
    Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
    Ząbczyk M; Blombäck M; Majewski J; Karkowski G; Wallen HN; Undas A; He S
    Thromb Haemost; 2015 Apr; 113(4):851-61. PubMed ID: 25518887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
    Ząbczyk M; Majewski J; Karkowski G; Malinowski KP; Undas A
    Thromb Res; 2015 Oct; 136(4):832-8. PubMed ID: 26319777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viscoelastic properties of plasma fibrin clots are similar in patients on rivaroxaban and vitamin K antagonists.
    Kopytek M; Zabczyk M; Natorska J; Siudut J; Malinowski KP; Ptaszek P; Glajcar A; Goralczyk T; Undas A
    J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome.
    Celinska-Löwenhoff M; Zabczyk M; Iwaniec T; Plens K; Musial J; Undas A
    Rheumatology (Oxford); 2018 Aug; 57(8):1340-1349. PubMed ID: 29672756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
    Goldman S; Frączek P; Szklanny K; Papuga-Szela E; Stanisz A; Undas A
    Thromb Haemost; 2018 Apr; 118(4):654-663. PubMed ID: 29618152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications.
    Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Dębski J; Podolak-Dawidziak M; Kuliczkowski K
    Blood Coagul Fibrinolysis; 2015 Sep; 26(6):621-7. PubMed ID: 26083985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Thompson PL; Verheugt FW
    Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice.
    Ząbczyk M; Ariëns RAS; Undas A
    Cardiovasc Res; 2023 Mar; 119(1):94-111. PubMed ID: 36662542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic drugs: part I.
    Gallus AS; Hirsh J
    Drugs; 1976; 12(1):41-68. PubMed ID: 789043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombosis and Aging: Fibrin Clot Properties and Oxidative Stress.
    Konieczyńska M; Natorska J; Undas A
    Antioxid Redox Signal; 2024 Aug; 41(4-6):233-254. PubMed ID: 38062775
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes.
    Ząbczyk M; Natorska J; Undas A
    J Clin Med; 2021 Jul; 10(13):. PubMed ID: 34279484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation.
    Drabik L; Wołkow P; Undas A
    Stroke; 2017 Oct; 48(10):2716-2722. PubMed ID: 28904234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure.
    Undas A; Natorska J
    Expert Rev Hematol; 2019 Aug; 12(8):597-607. PubMed ID: 31159611
    [No Abstract]   [Full Text] [Related]  

  • 19. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
    Drabik L; Wołkow P; Undas A
    Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
    PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.